Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.32
    OpenPayerPolicy UpdatesClinical/Medical PolicyHealthSpring Investigational Lab Coverage | OpenPa…
    Ask Trek AI about this page
    CurrentHealthSpringPolicy MED207.164

    Laboratory Testing Investigational Services

    Customize your policy alerts

    Sign up for healthspring Policy MED207.164 alerts

    Get alerted when Policy MED207.164 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs coverage of laboratory services considered experimental, investigational, and/or unproven when no separate medical policy provides specific testing criteria. It applies to providers and members whose benefit plans are subject to HealthSpring policy, subject to the member contract and applicable state regulations.

    Policy Summary
    PayerHealthSpring
    PolicyLaboratory Testing Investigational Services
    Policy CodePolicy MED207.164
    Change TypeNew policy
    Effective DateOctober 20, 2026
    Next Review DateN/A
    Key ActionReview the member’s benefit contract or Summary Plan Description for coverage, exclusions, and limitations before making a coverage determination.
    SourceLink
    POLICY UPDATE CHANGES

    New medical policy; all listed tests are classified as experimental, investigational, and/or unproven.

    AllListed tests classified as experimental, investigational, and/or unproven
    Insufficient evidenceBasis for noncoverage

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    High-complexity
    Required CLIA laboratory standard
    Separate criteriaWhen another policy applies
    44CPT codes listed
    NoneMedicare national coverage position

    Experimental and Investigational Testing

    Experimental, investigational, and/or unproven tests

    The policy applies to tests listed in this policy.

    Investigational laboratory testing: The test is considered experimental, investigational, and/or unproven because insufficient evidence exists to determine that the technology improves the net health outcome.

    The policy states that all tests listed in the policy fall into this category.

    Experimental, investigational, and/or unproven laboratory tests

    The tests listed in this policy are considered experimental, investigational, and/or unproven.

    Investigational classification: The listed test is considered experimental, investigational, and/or unproven because there is insufficient evidence to determine that the technology results in an improvement in the net health outcome.

    Coverage position must also be evaluated against the member's benefit contract or Summary Plan Description.

    CPT Codes

    Experimental CPT CodesCPTExperimental
    0616U
    0617U
    0618U
    0619U
    0620U
    0621U
    0622U
    0623U
    0624U
    0625U
    1–10 of 44
    1/5

    Coverage Determination Guidance

    Documentation Required

    Review Member Benefit Documents

    Review the member's benefit contract or Summary Plan Description (SPD) when making coverage determinations. Confirm defined coverage and non-coverage, benefit exclusions, and limitations such as dollar or duration caps.

    Denial Risk

    Investigational Status

    All tests listed in this policy are considered experimental, investigational, and/or unproven because there is insufficient evidence to determine that the technology improves the net health outcome.

    Note

    Separate Policy Criteria

    This policy applies only when no separate medical policy outlines specific criteria for the testing service. If a separate medical policy exists, its medical-necessity criteria supersede the guidelines in this policy.

    Policy Background

    This policy addresses laboratory tests offered in clinical practice before sufficient evidence of clinical validity and clinical utility has been established. Such tests may be proprietary and may lack independent evaluation data demonstrating their performance or usefulness in diagnosis, prognosis, risk assessment, or treatment decisions.

    Genetic Testing Terms

    Definitions
    VariantA change in the DNA sequence.
    Definitions
    Familial variantA disease-associated variant identified in a proband for use in subsequent targeted genetic testing in first-degree relatives.
    Definitions
    Pathogenic variantA disease-causing change in the DNA sequence.
    Definitions
    Likely pathogenic variant

    Noncovered Laboratory Services

    Laboratory services addressed by this policy are not covered when they are considered experimental, investigational, and/or unproven because evidence is insufficient to establish an improvement in the net health outcome. This includes testing in a developmental phase with limited evidence of clinical utility.

    Laboratory services covered by this policy may be denied when there is insufficient evidence of clinical benefit, including evidence that the technology improves the member’s net health outcome. Coverage remains subject to the member’s benefit contract or Summary Plan Description and any applicable exclusions or limitations.

    All tests listed in this policy are considered experimental, investigational, and/or unproven because the available evidence is insufficient to determine that the technology results in an improvement in the net health outcome.

    Policy Summary
    PayerHealthSpring
    PolicyLaboratory Testing Investigational Services
    Policy CodePolicy MED207.164
    Change TypeNew policy
    Effective DateOctober 20, 2026
    Next Review DateN/A
    Key ActionReview the member’s benefit contract or Summary Plan Description for coverage, exclusions, and limitations before making a coverage determination.
    SourceLink
    On This Page
    Experimental and Investigational TestingCPT CodesCoverage Determination GuidancePolicy BackgroundGenetic Testing TermsNoncovered Laboratory Services
    Denial Risk

    Investigational or Unproven Testing

    The tests addressed by this policy are often in a developmental phase, with limited evidence of clinical utility for diagnosis, prognosis, or risk assessment. Early proprietary testing may also lack independent evaluation data supporting performance and utility.

    Denial Risk

    Coverage Denial Risk

    Coverage may be denied because all tests listed in this policy are considered experimental, investigational, and/or unproven due to insufficient evidence of an improvement in the net health outcome.

    A likely disease-causing change in the DNA sequence.
    Definitions
    Variant of uncertain significanceA change in the DNA sequence with uncertain effects on disease.
    Definitions
    Clinically useful testA test is clinically useful when it provides information for a clinical management decision that improves the net health outcome; the balance of benefits and harms is better when the test is used to manage the condition than when another test or no test is used.
    Definitions
    Technical reliabilityThe test performs consistently and accurately from a technical standpoint. Technical reliability is outside the scope of these medical policies.
    Definitions
    PRSPolygenic risk score.